Predicting drug candidate victims of drug-drug interactions, using microdosing

Clinical Pharmacokinetics

Volumn 51, Issue 4, 2012, Pages 237-246

  Croft, Marie ^a,b   Keely, Brendan ^b   Morris, Ian ^b   Tann, Lan ^c   Lappin, Graham ^a  

^a Xceleron Ltd   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c SIMBEC RESEARCH LTD   (United Kingdom)

Author keywords

Caffeine; Drug interactions; Fexofenadine; Microdose therapeutics; Midazolam; Pharmacokinetics; Pharmacology; Tolbutamide.

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FEXOFENADINE; FLUVOXAMINE; GLYCOPROTEIN P; KETOCONAZOLE; MIDAZOLAM; TOLBUTAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INTERACTION; DRUG MICRODOSE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PREDICTIVE VALUE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; FLUVOXAMINE; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; P-GLYCOPROTEIN;

EID: 84858206981     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11597070-000000000-00000     Document Type: Article

References (35)

1. Hosea NA, Collard WT, Cole S, et al. Prediction of human pharmacokinetics from preclinical information: Comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 2009 May; 49 (5): 513-33
2. Nagilla R, Ward KW. A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci 2004 Oct; 93 (10): 2522-34
3. Ings R. Microdosing: A valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge. Bioanalysis 2009; 1 (17): 1293-305
4. Lappin G. Microdosing: Current and the future. Bioanalysis 2010 Mar; 2 (3): 509-17
5. RowlandM. Interview: Interview with ProfessorMalcolm Rowland. Bioanalysis 2010Mar; 2 (3): 385-91
6. International Conference on Harmonisation. ICH Topic M3 note for guidance on non-clinical safety pharmacology studies for human pharmaceuticals CPMP/ICH/286/95 (December 2009) [document reference: CPMP/ICH/286/95 2009; online]. Available from URL: Http://www.emea.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500002720.pdf [Accessed 2012 Jan 24]
7. Oosterhuis B. Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development. Bioanalysis 2010 Mar; 2 (3): 377-9
8. Yap YG, Camm J. Risk of torsades de pointes with non-cardiac drugs: Doctors need to be aware that many drugs can cause QT prolongation. BMJ 2000 Apr 29; 320 (7243): 1158-9
9. Yin OQ, Lam SS, Lo CM, et al. Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: Application to cytochrome P450 phenotyping studies. Rapid Commun Mass Spectrom 2004; 18 (23): 2921-33
10. Lappin G, Shishikura Y, Jochemsen R, et al. Pharmacokinetics of fexofenadine: Evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci 2010; 40: 125-31
11. Lappin G, Kuhnz W, Jochemsen R, et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs. Clin Pharmacol Ther 2006 Sep; 80 (3): 203-15
12. Vogel JS, Turteltaub KW. Accelerator mass spectrometry as a bioanalytical tool for nutritional research. In: Clifford AJ, Mueller SM, editors. Mathematical modelling in experimental nutrition. New York: Plenum Press, 1998: 397-410
13. Lappin G, Simpson M, Shishikura Y, et al. High-performance liquid chromatography accelerator mass spectrometry: Correcting for losses during analysis by internal standardization. Anal Biochem 2008 Mar 22; 378: 93-5
14. Simpson M. Development of 2D chiral chromatography with accelerator mass spectrometry for quantification of 14C-labeled R- and S-verapamil in plasma. Bioanalysis 2010; 2 (3): 397-405
15. Young G, Ellis W, Ayrton J, et al. Accelerator mass spectrometry (AMS): Recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica 2001 Aug-Sep; 31 (8-9): 619-32
16. Ogasawara A, Kume T, Kazama E. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab Dispos 2007 Mar; 35 (3): 410-8
17. Ieiri I, Doi Y, Maeda K, et al. Microdosing clinical study: Pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. J Clin Pharmacol. Epub 2011 May 18
18. Lappin G, Seymour M, Young G, et al. AMS method validation for quantitation in pharmacokinetic studies with concomitant extravascular and intravenous administration. Bioanalysis 2011 Feb; 3 (4): 393-405
19. He K, Qian M, Wong H, et al. N-in-1 dosing pharmacokinetics in drug discovery: Experience, theoretical and practical considerations. J Pharm Sci 2008 Jul; 97 (7): 2568-80
20. Culm-Merdek KE, von Moltke LL, Harmatz JS, et al. Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. Br J Clin Pharmacol 2005 Nov; 60 (5): 486-93
21. Fredholm BB, Battig K, Holmen J, et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999 Mar; 51 (1): 83-133
22. Robbins DK, Castles MA, Pack DJ, et al. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 1998 Oct; 19 (7): 455-63
23. Brunton LL, Lazo JS, Parker KL. Goodman and Gilman's: The pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006
24. Uchida S, Yamada H, Li XD, et al. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006 Nov; 46 (11): 1290-8
25. Balani SK, Nagaraja NV, QianMG, et al. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drug Metab Dispos 2006 Mar; 34 (3): 384-8
26. Chen C. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs R&D 2007; 8 (5): 301-14
27. Yamane N, Tozuka Z, Sugiyama Y, et al. Microdose clinical trial: Quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007 Oct 15; 858 (1-2): 118-28
28. Krishnaiah YS, Satyanarayana S, Visweswaram D. Interaction between tolbutamide and ketoconazole in healthy subjects. Br J Clin Pharmacol 1994 Feb; 37 (2): 205-7
29. Tsunoda SM, Velez RL, von Moltke LL, et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole. Clin Pharmacol Ther 1999 Nov; 66 (5): 461-71
30. Eap CB, Buclin T, Cucchia G, et al. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 2004 Jun; 60 (4): 237-46
31. GaletinA,Houston JB. Intestinal and hepaticmetabolic activity of five cytochrome P450 enzymes: Impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 2006 Sep; 318 (3): 1220-9
32. Madsen H, Enggaard TP, Hansen LL, et al. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clin Pharmacol Ther 2001 Jan; 69 (1): 41-7
33. Davit B, Reynolds K, Yuan R, et al. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: Impact on labeling. J Clin Pharmacol 1999 Sep; 39 (9): 899-910
34. Li J,WenSY,WangR, et al. Influence of cytochrome P450CYP2C9polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray [in Chinese]. Acta Pharm Sinica 2005 Aug; 40 (8): 695-9
35. Lucksiri A, Vuppalanchi R, Hilligoss JK, et al. Dose dependent inhibition of midazolam elimination by ketoconazole: Effect of CYP3A5 genotype. Clin Pharmacol Ther 2005; 77: 35